Related Experiment Videos
Effect of KE-298 on experimental arthritis in mice
Abstract:
KE-298 is a new immunomodulatory agent with a chemical structure similar to that of D-penicillamine. We compared the effects of KE-298 on type II collagen-induced arthritis (CIA) in mice with those of prednisolone. KE-298 at a dose of 25 mg/kg showed only a decrease in the progression of foot pad swelling. At doses of 50 and 100 mg/kg, however, KE-298 inhibited the severity and development of the collagen-induced arthritis index, the progression of foot pad swelling, bone damage and histopathological changes. These inhibitory effects were more pronounced at the dose of 50 mg/kg than at 100 mg/kg. KE-298 also significantly inhibited the delayed-type hypersensitivity (DTH) response to type II collagen, but did not affect the production of anti-type II collagen IgG antibody in arthritic mice. To determine the inhibitory mechanism of KE-298, we studied the effect of KE-298 on IL-1 beta and TNF-alpha production in mice. We found that KE-298 inhibited bacterial lipopolysaccharide (LPS)-induced IL-1 beta production at doses of 50 and 100 mg/kg. It inhibited the production of TNF-alpha at the dose of 50 mg/kg, but not at 100 mg/kg. In summary, at appropriate dosages, KE-298 inhibited CIA and TNF-alpha production in mice. KE-298 also inhibited the DTH reaction to type II collagen and LPS-induced IL-1 beta production in a dose-related fashion. These findings suggest that these effects of KE-298 are closely related to its immunomodulatory action.
Insights
KE-298, a novel immunomodulatory agent, effectively reduced collagen-induced arthritis (CIA) in mice. It suppressed key inflammatory markers like TNF-alpha and IL-1 beta, suggesting therapeutic potential for autoimmune diseases.
Area of Science:
- Immunology
- Pharmacology
- Rheumatology
Background:
- Rheumatoid arthritis is a chronic autoimmune disease characterized by joint inflammation and destruction.
- D-penicillamine is a drug used to treat rheumatoid arthritis, but its efficacy is limited.
- Novel immunomodulatory agents are needed to effectively treat rheumatoid arthritis with fewer side effects.
Purpose of the Study:
- To evaluate the efficacy of KE-298, a novel immunomodulatory agent, in a mouse model of collagen-induced arthritis (CIA).
- To compare the effects of KE-298 with prednisolone, a corticosteroid commonly used to treat arthritis.
- To investigate the underlying mechanisms of KE-298's anti-arthritic effects, including its impact on cytokine production and immune responses.
Main Methods:
- Collagen-induced arthritis (CIA) was established in mice.
- Mice were treated with varying doses of KE-298 (25, 50, and 100 mg/kg) or prednisolone.
- Arthritis severity was assessed by measuring paw swelling, arthritis index, bone damage, and histopathological changes.
- Delayed-type hypersensitivity (DTH) response to type II collagen and anti-type II collagen IgG antibody production were measured.
- Interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha) production were assessed following lipopolysaccharide (LPS) stimulation.
Main Results:
- KE-298 significantly inhibited the severity and progression of CIA at doses of 50 and 100 mg/kg, outperforming prednisolone in some aspects.
- The optimal dose for KE-298's anti-arthritic effects was 50 mg/kg, showing more pronounced inhibition than 100 mg/kg.
- KE-298 suppressed the DTH response to type II collagen but did not affect anti-collagen antibody production.
- KE-298 inhibited LPS-induced IL-1 beta production at 50 and 100 mg/kg and TNF-alpha production at 50 mg/kg.
Conclusions:
- KE-298 demonstrates significant therapeutic potential as an immunomodulatory agent for treating autoimmune arthritis.
- Its mechanism of action involves the suppression of key pro-inflammatory cytokines, including TNF-alpha and IL-1 beta.
- KE-298's efficacy and immunomodulatory properties suggest it could be a promising alternative or adjunct therapy for rheumatoid arthritis.